Clinical Trials Logo

Cataplexy Narcolepsy clinical trials

View clinical trials related to Cataplexy Narcolepsy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04923594 Completed - Narcolepsy Clinical Trials

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Start date: September 13, 2021
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-weeks.

NCT ID: NCT03881852 Completed - Narcolepsy Clinical Trials

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

CONCERT
Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) is a Phase 2, double-blind, randomized, placebo-controlled, crossover, multicenter trial of AXS-12 in patients with narcolepsy. Subjects meeting the entry criteria will be randomized in a 1:1 ratio either to placebo for three weeks followed by AXS-12 (up to 10 mg daily) for three weeks, or to AXS-12 (up to 10 mg daily) for three weeks followed by placebo for three weeks. Efficacy assessments will include the frequency of cataplexy attacks, and measures of other symptoms of narcolepsy.